Department of Endocrinology and Metabolism, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Department of Polymer Nano Science and Technology, Department of BIN Fusion Technology and BK-21 Polymer BIN Fusion Research Team, Chonbuk National University, Jeonju, Korea.
Endocrinol Metab (Seoul). 2021 Feb;36(1):146-156. doi: 10.3803/EnM.2021.879. Epub 2021 Feb 24.
The microencapsulation is an ideal solution to overcome immune rejection without immunosuppressive treatment. Poor biocompatibility and small molecular antigens secreted from encapsulated islets induce fibrosis infiltration. Therefore, the aims of this study were to improve the biocompatibility of microcapsules by dexamethasone coating and to verify its effect after xenogeneic transplantation in a streptozotocin-induced diabetes mice.
Dexamethasone 21-phosphate (Dexa) was dissolved in 1% chitosan and was cross-linked with the alginate microcapsule surface. Insulin secretion and viability assays were performed 14 days after microencapsulation. Dexa-containing chitosan-coated alginate (Dexa-chitosan) or alginate microencapsulated porcine islets were transplanted into diabetic mice. The fibrosis infiltration score was calculated from the harvested microcapsules. The harvested microcapsules were stained with trichrome and for insulin and macrophages.
No significant differences in glucose-stimulated insulin secretion and islet viability were noted among naked, alginate, and Dexa-chitosan microencapsulated islets. After transplantation of microencapsulated porcine islets, nonfasting blood glucose were normalized in both the Dexa-chitosan and alginate groups until 231 days. The average glucose after transplantation were lower in the Dexa-chitosan group than the alginate group. Pericapsular fibrosis and inflammatory cell infiltration of microcapsules were significantly reduced in Dexa-chitosan compared with alginate microcapsules. Dithizone and insulin were positive in Dexa-chitosan capsules. Although fibrosis and macrophage infiltration was noted on the surface, some alginate microcapsules were stained with insulin.
Dexa coating on microcapsules significantly suppressed the fibrotic reaction on the capsule surface after transplantation of xenogenic islets containing microcapsules without any harmful effects on the function and survival of the islets.
微囊化是克服免疫排斥而无需免疫抑制治疗的理想解决方案。包封胰岛分泌的较差的生物相容性和小分子抗原会引起纤维化浸润。因此,本研究的目的是通过地塞米松(Dexamethasone)涂层来提高微胶囊的生物相容性,并在链脲佐菌素诱导的糖尿病小鼠的异种移植中验证其效果。
地塞米松 21-磷酸酯(Dexa)溶解在 1%壳聚糖中,并与海藻酸钠微胶囊表面交联。微囊化 14 天后进行胰岛素分泌和活力测定。将含有地塞米松的壳聚糖包被的海藻酸钠(Dexa-chitosan)或海藻酸钠包被的猪胰岛移植到糖尿病小鼠中。从收获的微胶囊中计算纤维化浸润评分。用三氯乙酸和胰岛素以及巨噬细胞对收获的微胶囊进行染色。
裸微胶囊、海藻酸钠微胶囊和 Dexa-chitosan 包被的微胶囊的葡萄糖刺激胰岛素分泌和胰岛活力无显着差异。在移植微囊化的猪胰岛后,Dexa-chitosan 和海藻酸钠组的非空腹血糖均在 231 天内恢复正常。移植后 Dexa-chitosan 组的平均血糖水平低于海藻酸钠组。与海藻酸钠微胶囊相比,Dexa-chitosan 组的微胶囊囊周纤维化和炎症细胞浸润明显减少。Dexa-chitosan 胶囊中地塞米松和胰岛素呈阳性。尽管在表面上观察到纤维化和巨噬细胞浸润,但一些海藻酸钠微胶囊也被胰岛素染色。
在含有微胶囊的异种胰岛移植后,微胶囊表面的地塞米松涂层可显着抑制纤维化反应,而对胰岛的功能和存活无任何有害影响。